Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk
Top Cited Papers
- 16 February 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 121 (6) , 833-840
- https://doi.org/10.1161/circulationaha.109.192695
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Journal of Clinical Oncology, 2006
- Endocrine treatment of prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic HyperplasiaJournal of Urology, 1995